SELLAS Life Sciences reports 'promising' cancer vaccine PhII data; Aridis Pharmaceuticals gets NIH grant to develop vaccine storage tech;

> SELLAS Life Sciences announced that in a Phase II study of its WT1 cancer vaccine in malignant pleural mesothelioma patients, top-line data demonstrated clinical significant increases in overall survival and progression-free survival. Release

> Aridis Pharmaceuticals announced that it has received several National Institutes of Health grants, one of which is to develop technology to encase proteins into room temperature stable formulations for simpler vaccines storage. Release

> An attempt to repeal California's strict vaccination requirements for schoolchildren fell short of signatures. More

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.